Medioost SRL
Medioost reported total assets of 434,030 € at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Mar 2026).
The score of Medioost shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +19 % Total assets -58 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Medioost's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 23,767 € | ||||
| Equity | 422,516 € | ||||
| Cash | 221,179 € | ||||
| EBITDA | 75,688 € | ||||
| Total assets | 434,030 € |
Filed annual accounts
- Year ended 30 Sep 2025filed on 24 Mar 2026
- Year ended 30 Sep 2024filed on 14 Mar 2025
- Year ended 30 Sep 2023filed on 29 Mar 2024
- Year ended 30 Sep 2022filed on 22 Mar 2023
- Year ended 30 Sep 2021filed on 25 Mar 2022
Medioost's financial analysis
- Solvency97.3%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Medioost
Medioost's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0447.511.280
- VAT number
- BE0447511280
- Peppol
- Registered · 0208:0447511280 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 21 May 1992
- Registered office
- 2040 Antwerp
- Latest accounts
- 2025 · filed on 24 Mar 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Medioost (SRL) has been based in Antwerp since 1992, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 23,767 € and equity of 422,516 €; its revenue is not published. Its solvency stands at 97.3%, above the median of its sector (46.0%).
Companies similar to Medioost
Companies in the same business, of comparable size and area, outside its group.
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
- Launchpad Europe Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet 120,635 €
- Maimonides Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 142 €
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
- MiniMed Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet 8,076 €
- Medishop Wholesale of pharmaceutical and medical goods Aalst · balance sheet 420,688 €
- LD&C Medical Wholesale of pharmaceutical and medical goods Comblain-au-Pont · balance sheet 420,385 €
Frequently asked questions about Medioost
What is the revenue of Medioost?
Medioost files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Medioost?
In Belgium, the VAT number is the company number prefixed with BE: BE0447511280 for Medioost, if the company is VAT-registered. Its company number (CBE) is 0447.511.280.
Where is the registered office of Medioost?
According to the CBE register, the registered office of Medioost is in 2040 Antwerp.
What is the equity of Medioost?
At the close of the 2025 financial year, the equity of Medioost amounts to 422,516 €, a solvency of 97.3% of total assets.
Who manages Medioost?
The register lists 2 active mandates at Medioost. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Medioost
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →